Federal Trade Commission v. Vyera Pharmaceuticals, LLC
Case Number:
22-728
Court:
Nature of Suit:
Companies
Government Agencies
Sectors & Industries:
-
January 23, 2024
2nd Circ. Backs Shkreli Lifetime Pharma Industry Ban
The Second Circuit on Tuesday backed a ruling banning former pharmaceutical executive and convicted securities fraudster Martin Shkreli from the drug industry for life, saying a repeat of his past misconduct would be "life-threatening."
-
December 14, 2023
Shkreli's Lifetime Pharma Ban Goes Too Far, 2nd Circ. Told
An attorney for former pharmaceutical executive and convicted securities fraudster Martin Shkreli asked a Second Circuit panel to lift a lifetime industry ban on his client, saying it steps on Shkreli's First Amendment rights and bars him from other, unrelated sectors.
-
July 20, 2023
Shkreli Not Aided By Top Court's 'True Threat' Case, AGs Say
The Federal Trade Commission and a group of state attorneys general told the Second Circuit on Thursday that Martin Shkreli can't cite a U.S. Supreme Court decision defining when speech is a "true threat" to overturn his lifetime pharmaceutical industry ban.
-
July 13, 2023
Shkreli Argues 'True Threat' Case Backs Lifting Pharma Ban
Martin Shkreli has told the Second Circuit his appeal of a lifetime pharmaceutical industry ban is bolstered by the U.S. Supreme Court's recent decision that courts must consider a speaker's intent when deciding what is a "true threat."
-
April 14, 2023
Shkreli Keeps Fighting 'Needlessly Crushing' Penalties
Martin Shkreli pressed the Second Circuit on Thursday to overturn his $64.6 million fine and lifetime pharmaceutical industry ban imposed through a Federal Trade Commission and attorneys general antitrust case, arguing the ban is overbroad and his company should be fined, not him.